Using Thymidine Analogues to Measure Blood Flow in Tumors
Author Information
Author(s): Begg A C, Hofland I, Van Der Pavert I, Van Der Schueren B, Haustermans K
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Can the heterogeneity of labelling after thymidine analogue administration be related to perfusion variations and quantified as a perfusion indicator?
Conclusion
Changes in tumor blood flow can be reflected in the labelling of tumor cells by the thymidine analogue IdUrd, indicating its potential use as a perfusion indicator in tumors.
Supporting Evidence
- Perfusion in tumors was reduced by hydralazine and increased by nicotinamide.
- Flow cytometry showed a 50% decrease in IdUrd labelling after hydralazine treatment.
- Almost 50% of vessels had no IdUrd labelling after hydralazine, compared to 2.9% in control animals.
Takeaway
This study found that how well tumor cells take up a special dye can show how well blood is flowing to the tumor, which is important for understanding cancer treatment.
Methodology
Perfusion in murine RIF1 tumors was manipulated using hydralazine and nicotinamide, followed by IdUrd injection, with analysis through flow cytometry and immunohistochemistry.
Participant Demographics
Murine RIF1 tumors were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website